GLP-1 outcomes, epilepsy insights, clinical trials, and more In this issue, explore new real-world evidence comparing obesity therapies, and see how real-world data is helping accelerate clinical evidence generation
patients interested in the current development status or trial availability should consult the manufacturer's communications or the ClinicalTrials
3 Works cited FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, accessed February 2, 2026, Semaglutide Shortage Resolved McDermott Will & Schulte, accessed February 2, 2026, GLP-1 Update: Court Backs FDA in Tirzepatide Compounding Case, accessed February 2, 2026, The Return of 503B Compounding of GLP-1 Medications Frier Levitt, accessed February 2, 2026, The Strategic Imperative of Pharmaceutical Competitor Analysis: A Comprehensive Guide for 2026 and Beyond DrugPatentWatch, accessed February 2, 2026, Maximizing ROI on Drug Development by Monitoring Competitive Patent Portfolios, accessed February 2, 2026, Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act FDA, accessed February 2, 2026, GLP-1 Weight-Loss Drugs Off Shortage List
Others prefer three structured meals with planned, protein-rich snacks
Pull the outer cap off, but do not throw it away
Association between hospital-diagnosed tinnitus and suicide: A nationwide Danish longitudinal study
